JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Clinical lipidologists frequently manage patients with severely elevated low-density lipoprotein cholesterol (LDL-C).
• Maximum statin doses combined with other drugs may not sufficiently reduce LDL-C in these individuals.
• Genetic abnormalities in the LDL receptor gene often cause the most extreme LDL-C elevations, exceeding 400 mg/dL and showing limited response to existing treatments.

Purpose of the Study:

• To provide guidance on the prescription use of newly approved drugs for managing severe hypercholesterolemia.
• To discuss the clinical application of mipomersen and lomitapide in patients with genetic lipid disorders.
• To address key questions regarding the management of patients with refractory high LDL-C.

Main Methods:

• Discussion and Q&A session between expert clinician scientists.
• Review of clinical research studies involving mipomersen and lomitapide.
• Focus on practical aspects of prescribing these novel agents.

Main Results:

• Mipomersen and lomitapide have been approved by the FDA for specific patient populations with severe hypercholesterolemia.
• These agents represent new therapeutic options for patients with genetic conditions causing extremely high LDL-C.
• Expert insights were shared on the effective and safe use of these medications.

Conclusions:

• Mipomersen and lomitapide offer important new treatment avenues for patients with severe, genetically driven hypercholesterolemia.
• Effective management of refractory LDL-C requires consideration of these advanced pharmacological interventions.
• Further clinical experience and data will refine the optimal use of these drugs.